2013
DOI: 10.1111/bju.12438
|View full text |Cite
|
Sign up to set email alerts
|

Bladder outlet obstruction (BOO) in men with castration‐resistant prostate cancer

Abstract: Objective• To evaluate the frequency of bladder outlet obstruction (BOO) and detrusor overactivity (DO) in patients with castration-resistant prostate cancer (CRPC) and lower urinary tract symptoms (LUTS). Patients and Methods• Our prospective urodynamics database was queried.• Inclusion criteria were CRPC and an International Prostate Symptom Score (IPSS) ≥ 20.• Exclusion criteria were previous local therapy to the prostate gland, known urethral stricture disease, and a neurological component of LUTS.• Twenty… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
1
1

Year Published

2014
2014
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 21 publications
0
3
1
1
Order By: Relevance
“…They had smooth urination. Studies suggest that more than half of castrated resistant prostate cancer patients have detrusor overactivity [15]. In our study, only a case had a little urinary incontinence during daytime activities, but no urinary incontinence at night.…”
Section: Discussioncontrasting
confidence: 46%
“…They had smooth urination. Studies suggest that more than half of castrated resistant prostate cancer patients have detrusor overactivity [15]. In our study, only a case had a little urinary incontinence during daytime activities, but no urinary incontinence at night.…”
Section: Discussioncontrasting
confidence: 46%
“…It should be emphasized that these patients in our study differed from patients with iPC or established PC accompanied by bladder outlet obstruction; the late was common during clinical practice [10]. For the latter population, TURP could bring symptom relief and PSA benefits [1,11,12]. Nevertheless, TURP may increase the risk of death for these patients [13,14].…”
Section: Introductionmentioning
confidence: 82%
“…[31] Previous studies have both corroborated [32] and refuted [33] the potential cytoreductive advantage of cTURP. With regards to symptom resolution, though most patients experience postprocedural improvement, re-cTURP rates range from 4 to 30% [34,35].…”
Section: Prostate Cancermentioning
confidence: 99%